Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?

被引：23
|
作者：
Kumarasamy, N. [1 ,3 ]
Patel, Atul [2 ,3 ]
Pujari, Sanjay [3 ,4 ]
机构：
[1] YRG CARE Med Ctr, Voluntary Hlth Serv, Madras 600113, Tamil Nadu, India
[2] Vedant Inst Med Sci, Ahmadabad, Gujarat, India
[3] Inst Infect Dis, Pune, Maharashtra, India
[4] HIVMAI, Pune, Maharashtra, India
来源：
INDIAN JOURNAL OF MEDICAL RESEARCH | 2011年 / 134卷 / 06期
基金：
英国惠康基金;
关键词：
Antiretroviral drugs; antiretroviral therapy; ART; CD4; HIV; IRIS; viral load; RECONSTITUTION INFLAMMATORY SYNDROME; HIV-INFECTED PATIENTS; CD4 CELL COUNTS; COST-EFFECTIVENESS ANALYSIS; ZIDOVUDINE-INDUCED ANEMIA; LONG-TERM EFFICACY; LINE VIRAL LOAD; IMMUNE RECONSTITUTION; RISK-FACTORS; DRUG-RESISTANCE;
D O I：
10.4103/0971-5916.92626
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
With the rapid scale up of antiretroviral therapy, there is a dramatic decline in HIV related morbidity and mortality in both developed and developing countries. Several new safe antiretroviral, and newer class of drugs and monitoring assays are developed recently. As a result the treatment guideline for the management of HIV disease continue to change. This review focuses on evolving science on Indian policy - antiretroviral therapy initiation, which drugs to start with, when to change the initial regimen and what to change.
引用
收藏
页码：787 / 800
页数：14
相关论文
共 50 条
12345